Key facts
- Granata Bio’s last known valuation is $129.0M (Dec 2024).
- It has raised $31.1M across 2 recorded rounds; the latest was Early Stage VC ($13.8M) in Dec 2024.
- Notable investors include Alumni Ventures, Mana Ventures, Gaingels, GV, What If Ventures — 9 tracked in total.
- Granata Bio has filed 2 Form Ds with the SEC since 2023, most recently Dec 2024 ($13.8M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Granata Bio
Funding rounds
2 roundsAbout Granata Bio
Operator of a biopharma company intended to find and grow fertility programs for patients. The company creates a robust fertility therapeutic portfolio and brings expertise in commercialization as well as late-stage clinical and regulatory development, enabling medical professionals to overcome significant barriers to fertility treatment.
- Sector
- Healthcare
- HQ
- Duxbury, MA, United States
- Founded
- 2018
- Employees
- 16
- Website
- granata.bio/
- Ownership
- Privately Held (backing)
Granata Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Granata Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Granata Bio in its N-PORT filings yet. We sweep new filings monthly.